Pingbeimine B is primarily studied for its potential antitumor and anticancer properties. It has shown inhibitory effects on the proliferation of certain cancer cell lines, particularly in lung and liver cancers, by inducing apoptosis and cell cycle arrest. Research also suggests it may interfere with tumor angiogenesis, limiting the formation of new blood vessels that support tumor growth. Additionally, Pingbeimine B exhibits anti-inflammatory activity, which could contribute to its overall therapeutic effect in cancer and chronic inflammatory conditions. Most of the current applications are within preclinical research, focusing on drug development and understanding molecular pathways in oncology.